SHZ Healthcare Biotechnology 300204.SZ

Staidson (Beijing) BioPharmaceuticals Co., Ltd.

$ 20.50 1.94 %

Staidson (Beijing) BioPharmaceuticals Co., Ltd. is a Chinese biopharmaceutical company that specializes in the entire lifecycle of therapeutic drugs, from research and development to production and market distribution. Their product portfolio encompasses a variety of drug types, including advanced protein-based medicines like therapeutic monoclonal antibodies, innovative gene and cell therapies, and conventional chemical pharmaceuticals. The company's primary therapeutic areas address conditions related to the nervous system, infectious diseases, gastrointestinal health, the urinary system, and autoimmune disorders. Notably, Staidson has established a strategic partnership with Pivotal S.L. to conduct clinical trials in Europe for BDB-001, a monoclonal anti-C5a antibody, aimed at treating patients with severe, progressive COVID-19 caused by the SARS-CoV-2 virus. Founded in 2002, the company's headquarters are located in Beijing, China.

CEO: Wang Chao - https://www.staidson.com

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

-

Recommandation

-

DCF

$ -1.37

Loading data...

300204.SZ vs S&P500

Loading data...

No data available.

Quick ratio

1.85

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

-113.89

may indicate that the company is undervalued or has poor growth prospects.

EPS

-0.18

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

-9.45 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

-7.45 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

6.27

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.15

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

-0.46

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

-1.08 %

indicates that the company is retaining a large portion of its profits to reinvest in growth

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
2 indicates worrying financial health
Altman score
11.61 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.98 indicates that the company has a moderate ability to cover its short-term debts with its cash
Debt Ratio
0.09 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.